Compare Dicks Sporting Goods Inc (DKS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Dicks Sporting Goods Inc trades at $136.65 (market cap $13.26B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Dicks Sporting Goods Inc is the larger of the two by market cap, and Dicks Sporting Goods Inc pays a 3.71% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dicks Sporting Goods Inc for 19 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| DKS | XBI | |
|---|---|---|
Market Cap | $13.26B | $10.11B |
Volume | 2,292,035 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $239.17 | $169.55 |
52-Week Low | $121.15 | $104.99 |
Typical Hold Time | 19 Days | 38 Days |
Enterprise Value | $20.31B | — |
Dividend Yield | 3.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DICK'S Sporting Goods (DKS) trades at $134.63, up 2.63% today, with a bearish technical signal and mixed earnings history. The stock shows strong profitability with an 18.47% ROE and trades at a discount with a P/E of 14.86 and P/S of 0.57. Recent news highlights a securities class action lawsuit, while the company maintains a solid dividend and analyst consensus remains positive.
The outlook is cautious due to legal overhangs and a recent earnings miss, but the stock offers value with a consensus price target of $153.30. Upside potential exists if the company navigates litigation and maintains operational strength, though risks from competitive pressures and macroeconomic factors persist.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
